top of page
UMM.jpeg

The Immunomodulation Lab

Our group investigates the interplay between immune cells and various disease including cancer and inflammation in vivo. Our aim is to understand the mechanism that control immunity and to identify novel targets for cancer immunotherapy.

We focussing on (1) CAR t-cells and (2) neutrophile extracellular traps (NETs).

 

Pediatric Tumors are particularly immunogenic. We develop and implement cutting-edge CAR t-cell technologies to control or eliminate cancer and to modulate the immune system. In our lab we combine  and  into novel therapeutic strategies which will ultimately benefit children suffering from cancer or immune disease.

NETs confer protection against infections, but also drive inflammation and immunopathology.

The Team

Michael_H5.jpg

Michael Boettcher

Lab Director

Innate Immunity and CAR t-cells: NETs, Immunomodulation, Visulalisation, personalized Immunotherapy

Bildschirmfoto 2021-09-14 um 13_edited.jpg

Julia Elrod

Senior Researcher

Innate Immunity: NETs, transplantation, burns, wound healing, microcirculation

csm_Martel__Richard_7d8a4c5f8d.jpeg

Richard Martel

Researcher

Innate Immunity: NETs, NEC, CDH, ECMO, organoids

Knopf_Jasmin.jpeg

Jasmin Knopf

PostDoc/Head of Research Lab

Innate Immunity: NETs, adhesion formation, NEC, CDH, ECMO

csm_Blum_Laura_quer_3942e1cbf3.jpg

Laura Blum

PhD student

The role of NETs in NEC

csm_Yuqing_Lu_quadrat_2f39363605.jpg

Yuqing Lu

MD student

Therapeutical inhibition of NETs in adhesion

csm_Jank_Marietta_cc8594735b.jpg

Marietta Jank

Researcher

Innate Immunity: CDH, ECMO

csm_Trautmann_Tina_Quadrat_06fd5303f9.png

Tina Trautmann

Researcher

Pediatric solid tumors: CAR t-cells, immunity, microbioma

csm_20_M3_JB_Gallensteine_08_fe552f637f_edited.jpg

Martin Herrmann

Senior Advisor

Professor Martin Herrmann is Head of the Immunology Lab at Erlangen University. 

 

Innate Immunity: neutrophils, neutrophil extracellular traps

Biosceptre_Team_Patrick-Schlegel_edited.jpg

Patrick Schlegel

Senior Advisor

Professor Patrick Schlegel is Head of Cellular Cancer Therapeutics at the Children's Hospital Westmead, University Sydney

Pediatric solid tumors: next generation CAR-T design

bottom of page